Key Takeaway
Learn which health conditions qualify you for GLP-1 treatment, how they're documented, and what providers look for. Take our free quiz.
Medically reviewed by Dr. Rachel Torres, PharmD (Clinical Pharmacist, compounding pharmacy specialist
Not everyone who wants GLP-1 medication needs a BMI over 30 to qualify. This health conditions qualify GLP-1 resource covers the important information you need to make informed decisions. Certain health conditions qualify you for GLP-1 treatment even at a lower BMI. These qualifying comorbidities are medical conditions that are caused by, or made worse by, carrying extra weight.
Key Takeaways: - Type 2 Diabetes and Prediabetes - Cardiovascular Conditions - Metabolic and Hormonal Conditions - Sleep, Joint, and Quality-of-Life Conditions - Conditions That Don't Qualify (And Why)
Understanding which conditions qualify you is the first step. Knowing how they're documented and what your provider looks for is just as important. This guide covers every major qualifying condition in detail so you can walk into your consultation prepared and confident.
If you're wondering whether your specific situation qualifies, take our free eligibility quiz for a quick answer.
Type 2 Diabetes and Prediabetes
Type 2 diabetes is one of the strongest qualifying conditions for GLP-1 treatment. In fact, GLP-1 receptor agonists like semaglutide were first approved specifically for blood sugar management before their weight loss benefits were widely recognized.
If you have a diagnosis of type 2 diabetes, you almost certainly qualify. But you don't need a full diabetes diagnosis. Prediabetes counts too. This means your A1C is between 5.7% and 6.4%, or your fasting blood glucose runs between 100 and 125 mg/dL.
Your provider documents this through lab work. A simple blood test measuring your A1C or fasting glucose confirms the diagnosis. Many people don't realize they have prediabetes because it rarely causes symptoms. Your GLP-1 consultation may actually be how you first learn about it.
Clinical trials have shown that GLP-1 medications can help reduce A1C levels by 1-2 percentage points while simultaneously supporting weight loss. This dual benefit makes them particularly valuable for people with both diabetes and excess weight.
Insulin Resistance. Even without a prediabetes diagnosis, insulin resistance may qualify you. Signs include difficulty losing weight despite diet and exercise, darkened skin patches (acanthosis nigricans), and fatigue after meals. Your provider can order a fasting insulin level to check.
Cardiovascular Conditions
Heart and blood vessel conditions are common qualifying comorbidities. They're well-documented in medical literature and easy for providers to verify.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
Hypertension (High Blood Pressure). If your blood pressure consistently reads above 130/80 mmHg, you have hypertension. This is one of the most common qualifying conditions. Excess weight increases blood volume and puts more strain on artery walls. Preliminary data suggest that weight loss of 5-10% can reduce blood pressure by meaningful amounts.
"The key to successful GLP-1 therapy is setting realistic expectations and supporting patients through the titration phase. The side effects are manageable for most people, but they need to know what to expect.") Dr. Caroline Apovian, MD, Harvard Medical School
Your provider documents hypertension through blood pressure readings, a current prescription for blood pressure medication, or a prior diagnosis in your medical records. If you're already taking medication for high blood pressure, that counts as documentation.
High Cholesterol and Dyslipidemia. improved LDL cholesterol, low HDL cholesterol, or high triglycerides qualify as comorbidities. Your provider verifies this with a lipid panel blood test. If you're currently taking statins or other cholesterol medication, that serves as documentation too.
Cardiovascular Disease. A history of heart attack, stroke, or diagnosed coronary artery disease is a strong qualifying condition. These conditions make weight management medically urgent, and your provider will have clear documentation in your medical history.
Research published in the New England Journal of Medicine has shown that semaglutide may reduce the risk of major cardiovascular events in people with established heart disease. This is one reason providers take cardiovascular comorbidities seriously when evaluating GLP-1 eligibility.
Free Download: GLP-1 Eligibility Self-Assessment Checklist Go through each qualifying condition step by step before your consultation. This checklist helps you organize your medical history so your provider has everything they need. Get yours free (we'll email it to you instantly. [Download Your Free Checklist]
Metabolic and Hormonal Conditions
Several metabolic and hormonal conditions are recognized as qualifying comorbidities for GLP-1 treatment.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Patient Perspective: "I was surprised I qualified) I didn't think of myself as 'obese enough' for medication. But my BMI was 32 with high blood pressure, and my provider explained that's exactly who these medications were designed for.", Nicole F., 42, FormBlends patient (name changed for privacy)
Polycystic Ovary Syndrome (PCOS). PCOS affects up to 12% of women of reproductive age. It's characterized by irregular periods, improved androgens, and often insulin resistance. Many women with PCOS struggle with weight gain that feels impossible to control through diet alone.
Providers document PCOS through a combination of symptoms, hormone levels, and sometimes ultrasound findings. If you've been diagnosed by a gynecologist or endocrinologist, that counts. GLP-1 medications may help with both weight management and metabolic symptoms of PCOS.
Non-Alcoholic Fatty Liver Disease (NAFLD). This condition means fat has built up in your liver without heavy alcohol use being the cause. It affects about 25% of adults and is strongly linked to excess weight and insulin resistance.
NAFLD is documented through improved liver enzymes on a blood test, imaging like ultrasound, or a prior diagnosis. Many people discover they have NAFLD incidentally during routine bloodwork. Emerging clinical data suggests GLP-1 medications may help reduce liver fat.
Metabolic Syndrome. This isn't a single condition but a cluster of risk factors: high blood sugar, high blood pressure, excess abdominal fat, and abnormal cholesterol levels. Having three or more of these risk factors together qualifies as metabolic syndrome and represents a strong case for GLP-1 eligibility.
If you want to understand how GLP-1 medications compare across these conditions, our semaglutide vs. Tirzepatide guide breaks down the differences.
Sleep, Joint, and Quality-of-Life Conditions
Some qualifying conditions are about how excess weight affects your daily functioning and long-term health risks.
Obstructive Sleep Apnea (OSA). This condition causes your airway to collapse during sleep, leading to interrupted breathing, snoring, and poor sleep quality. OSA is strongly associated with excess weight, particularly fat around the neck and throat.
Documentation can include a formal sleep study diagnosis, use of a CPAP machine, or a referral for sleep evaluation. Even if you haven't had a formal sleep study, your provider may consider symptoms like loud snoring, witnessed breathing pauses, excessive daytime sleepiness, and morning headaches.
Osteoarthritis. Weight-bearing joints like knees and hips take extra punishment from excess weight. If you have diagnosed osteoarthritis that limits your mobility, this can qualify as a comorbidity. The logic is straightforward: losing weight reduces joint stress and can improve mobility and pain levels.
Depression Related to Weight. Some providers consider clinically documented depression that's worsened by weight as a qualifying factor. This requires a formal diagnosis and documentation showing the connection between weight and mental health. You can read more about the connection in our guide to mental health and weight management.
Your provider looks at how these conditions interact with each other. Having multiple comorbidities strengthens your case for GLP-1 treatment, even if no single condition feels severe on its own.
Conditions That Don't Qualify (And Why)
Not every health condition makes you eligible for GLP-1 treatment. Knowing what doesn't qualify can save you time and set the right expectations.
Cosmetic weight loss goals alone. If your BMI is below 27 and you don't have any weight-related comorbidities, GLP-1 medications are generally not indicated. These medications are designed for people whose excess weight is causing or worsening medical conditions.
Eating disorders. Active eating disorders like anorexia nervosa or bulimia are typically contraindications for GLP-1 treatment. The appetite-suppressing effects of these medications can worsen disordered eating patterns. Your provider screens for this during your consultation to keep you safe.
Pregnancy or planned pregnancy. GLP-1 medications aren't recommended during pregnancy or for people actively trying to conceive. Most guidelines recommend stopping GLP-1 treatment at least two months before planned conception. If you're in this situation, discuss the timing with your provider.
History of medullary thyroid carcinoma or MEN 2. A personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2 is a contraindication for GLP-1 medications. Your provider will ask about this during your screening.
If you have questions about whether your specific situation qualifies, the fastest way to find out is through a provider consultation. Your provider can evaluate conditions that fall into gray areas and make a clinical determination based on your individual case.
How to Prepare Your Documentation
Walking into your consultation prepared saves time and helps your provider make an accurate assessment. Here's what to gather.
Current medications. List every prescription you take, including dosage. Blood pressure meds, statins, metformin, and CPAP use all serve as documentation of qualifying conditions. Don't forget over-the-counter supplements and vitamins, as some may be relevant.
Recent lab work. If you've had bloodwork in the past 12 months, bring results or have them available. Relevant labs include A1C, fasting glucose, lipid panel, and liver enzymes. If you don't have recent labs, your provider can order them. Having results ready can speed up the approval process by days.
Diagnosis history. Note any formal diagnoses you've received, along with which doctor diagnosed you and approximately when. Even conditions diagnosed years ago remain relevant. Include surgeries, hospitalizations, and specialist visits related to your weight or qualifying conditions.
Symptom journal. If you suspect a condition but haven't been formally diagnosed, writing down your symptoms helps your provider evaluate. Note things like how often you wake up at night, joint pain locations, energy levels, and menstrual irregularities. Include how long you've experienced each symptom and whether it's getting worse.
Weight history. Your provider will want to know your highest adult weight, how long you've been at your current weight, and what previous weight loss methods you've tried. This context helps them understand your full picture and build a treatment plan that addresses your unique challenges.
FormBlends providers are trained to look at your complete health picture. The eligibility quiz asks targeted questions about these conditions to give you a preliminary answer before you even speak with a provider.
You can also track your health data over time with the FormBlends app, which makes it easy to share trends with your provider.
Frequently Asked Questions
Do I need documentation for every qualifying condition?
Not necessarily. Your provider can evaluate based on your reported symptoms, current medications, and medical history. But having lab work or a prior diagnosis makes the process faster. If documentation is needed, your provider can order the appropriate tests.
Can I qualify with just one comorbidity?
Yes. A single qualifying comorbidity paired with a BMI of 27 or higher can make you eligible for GLP-1 treatment. Having multiple conditions isn't required, though it does strengthen the clinical case.
What if I think I have a condition but haven't been diagnosed?
That's more common than you think. Many conditions like prediabetes, NAFLD, and sleep apnea go undiagnosed for years. Your provider can evaluate your symptoms and order appropriate testing during or after your consultation.
Does family history of these conditions matter?
Family history alone doesn't qualify you, but it provides important context. If your parent or sibling has type 2 diabetes and you're showing early signs of insulin resistance, your provider takes that into account when evaluating your overall risk profile.
How quickly can I find out if I qualify?
The eligibility quiz takes about two minutes and gives you a preliminary answer immediately. If you move forward with a consultation, most providers can make an eligibility determination within the first visit, often the same day.
What's Your Next Move?
You have the information. Now let a licensed provider help you put it into action. FormBlends makes it simple, answer a few questions and get a personalized recommendation.
Medical References
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3). JAMA. 2021;325(14):1403-1413. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28(10):2083-2091. [PubMed | ClinicalTrials.gov | DOI]
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide with intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2024. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2 (Davies et al., Lancet, 2021)). Lancet. 2021;397(10278):971-984. Doi:10.1016/S0140-6736(21)00213-0
- Wadden TA, Bailey TS, Billings LK, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity (STEP 3 (Wadden et al., JAMA, 2021)). JAMA. 2021;325(14):1403-1413. Doi:10.1001/jama.2021.1831
- Garvey WT, Batterham RL, Bhatt DL, et al. Two-Year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5 (Garvey et al., Nat Med, 2022)). Nat Med. 2022;28:2083-2091. Doi:10.1038/s41591-022-02026-4
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Doi:10.1056/NEJMoa2307563
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2[4] (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3[5] (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4[6] (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
- Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816
Nothing in this article should be construed as medical advice. The information provided is educational only. Always consult with your healthcare provider before beginning, modifying, or discontinuing any medication or treatment. FormBlends connects patients with licensed providers for individualized care.
Last updated: 2026-03-24